Pfizer Vaccine Inc.
/ Bionech SE Covid-19 is 93 percent effective in preventing hospitalization between those aged 12 to 18, according to an analysis issued by US centers for controlling and prevention of disease (CDC) on Tuesday.
This study was conducted between June and September, when the Delta variant was very contagious from the dominant Coronavirus.
However, data from 19 pediatric hospitals showed that among 179 patients treated in hospitals for Covid-19, 97 percent were not vaccinated, providing guarantees of the efficacy of the vaccine.
Of the approximately 16 percent of patients treated in hospitals with Covid-19 which are quite severely needing living support, no vaccinated.
The CDC report built a trial conducted by the company in this age group which showed a high immune response to the virus, but which was not designed to show efficacy of inpatient care.
The Pfizer / Biontech vaccine was passed for children as young as 12, and the company was looking for authorization to be used to them as young as five years old.
Panels of advisors for US food and drug administration are expected to burden data in small children this month.
CDC data “strengthens the importance of vaccination to protect US young people against severe Covid,” said the research writers.
Pfizer Vaccine / Bionech Covid-19 is very protective in the age group 12-18: US CDC Study
